Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Greenwich LifeSciences, Inc. (GLSI : NSDQ)

• Company Description    Greenwich LifeSciences Inc. is a clinical stage biopharmaceutical company focuses on the development of cancer immunotherapies for breast cancer and other human epidermal growth factor. The company's product candidate includes GP2, which is in clinical stage. Greenwich LifeSciences Inc.is based in Stafford, Texas. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $12.98 Daily Weekly Monthly 20 Day Moving Average: 187,647 shares Shares Outstanding: 14.68 (millions) Market Capitalization: $190.52 (millions) Beta: 1.40 52 Week High: $34.10 52 Week Low: $7.78 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -29.19% -29.71% 12 Week -45.05% -46.55% Year To Date -38.22% -41.99%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3992 BLUEBONNET DR BUILDING 14 - STAFFORD,TX 77477 USA ph: 832-819-3232 fax: - info@greenwichlifesciences.com https://greenwichlifesciences.com

• General Corporate Information    Officers Snehal Patel - Chief Executive Officer and Director F. Joseph Daugherty - Chief Medical Officer and Director David McWilliams - Director Eric Rothe - Director Kenneth Hallock - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 396879108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 14.68 Most Recent Split Date: (:1) Beta: 1.40 Market Capitalization: $190.52 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.38 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 34.12 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -56.00% vs. Previous Quarter: 32.76% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -941.15 12/31/25 - -1,464.02 ROA 06/30/26 - - 03/31/26 - -368.53 12/31/25 - -488.19 Current Ratio 06/30/26 - - 03/31/26 - 2.01 12/31/25 - 1.06 Quick Ratio 06/30/26 - - 03/31/26 - 2.01 12/31/25 - 1.06 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 0.38 12/31/25 - 0.03 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©